XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation

· Financial Post

Read More

Visit biznow.biz for more information.

Read full story at source